These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11054262)

  • 1. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma.
    Haas DW; Clough LA; Johnson BW; Harris VL; Spearman P; Wilkinson GR; Fletcher CV; Fiscus S; Raffanti S; Donlon R; McKinsey J; Nicotera J; Schmidt D; Shoup RE; Kates RE; Lloyd RM; Larder B
    AIDS Res Hum Retroviruses; 2000 Oct; 16(15):1491-502. PubMed ID: 11054262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.
    Foudraine NA; Hoetelmans RM; Lange JM; de Wolf F; van Benthem BH; Maas JJ; Keet IP; Portegies P
    Lancet; 1998 May; 351(9115):1547-51. PubMed ID: 10326538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
    Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
    AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
    Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients.
    Karlström O; Ståhle L; Perrin L; Tegude H; Sönnerborg A
    Scand J Infect Dis; 2006; 38(5):371-4. PubMed ID: 16709540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
    Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M
    BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zidovudine and lamivudine reach higher concentrations in ventricular than in lumbar human cerebrospinal fluid.
    Eggers C; Hoetelmans R; Läer S
    AIDS; 2020 Nov; 34(13):1883-1889. PubMed ID: 32694416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system.
    Martin C; Sönnerborg A; Svensson JO; Ståhle L
    AIDS; 1999 Jul; 13(10):1227-32. PubMed ID: 10416527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex.
    Aweeka F; Jayewardene A; Staprans S; Bellibas SE; Kearney B; Lizak P; Novakovic-Agopian T; Price RW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan; 20(1):39-43. PubMed ID: 9928728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
    J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients.
    Chien JW; Valdez H; McComsey G; McClernon D; St Clair M; Lederman MM
    J Acquir Immune Defic Syndr; 1999 Aug; 21(4):277-80. PubMed ID: 10428105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
    Hoetelmans RM; Reijers MH; Weverling GJ; ten Kate RW; Wit FW; Mulder JW; Weigel HM; Frissen PH; Roos M; Jurriaans S; Schuitemaker H; de Wolf F; Beijnen JH; Lange JM
    AIDS; 1998 Jul; 12(11):F111-5. PubMed ID: 9708400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular analysis of cerebrospinal fluid: potential for the study of HIV-1 infection of the central nervous system.
    Cinque P; Bestetti A; Morelli P; Presi S
    J Neurovirol; 2000 May; 6 Suppl 1():S95-S102. PubMed ID: 10871772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
    Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
    Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.
    Polis MA; Suzman DL; Yoder CP; Shen JM; Mican JM; Dewar RL; Metcalf JA; Falloon J; Davey RT; Kovacs JA; Feinberg MB; Masur H; Piscitelli SC
    AIDS; 2003 May; 17(8):1167-72. PubMed ID: 12819518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.